---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-031332"
form_type: "8-K"
ticker: "INMB"
cik: "0001711754"
company_name: "Inmune Bio, Inc."
filed_at: "2023-04-20T23:59:59+00:00"
generated_at: "2026-06-16T22:36:17.703901+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# INmune Bio amends license agreements, removes clinical milestones; reports XPro1595 pre-clinical data in TBI-AD model

## Summary
- Amended INKmune license with Immune Ventures: removed all due diligence including clinical trial and NDA filing requirements.
- Amended PITT license: replaced milestones with Phase II first patient dose by June 2026, marketing authorization by June 2031.
- Pre-clinical study shows XPro1595 prevents amyloid pathology in mouse model of TBI-induced Alzheimer's disease.
- Data presented at AD/PD 2023 conference in Gothenburg, Sweden on April 1, 2023.
- XPro1595 neutralizes soluble TNF without affecting transmembrane TNF; currently in clinical trials for neurologic disease.

## SEC filing metadata
- accession: 0001213900-23-031332
- form_type: 8-K
- ticker: INMB
- cik: 0001711754
- company_name: Inmune Bio, Inc.
- filed_at: 2023-04-20T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1711754/000121390023031332/0001213900-23-031332-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711754/000121390023031332/ea177097-8k_inmunebio.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-031332
- JSON: https://secwatch.observer/filing/0001213900-23-031332.json
- Plain text: https://secwatch.observer/filing/0001213900-23-031332.txt

## Key facts
- Material Agreements
  Inmune Bio, Inc. amended Second PITT Amendment with University of Pittsburgh (effective 2023-04-17).
  - Action: amendment
  - Agreement: license
  - Counterparty: University of Pittsburgh
  - Effective: 2023-04-17
  source text: On April 17, 2023, the Company entered into the Second Amendment to Exclusive License Agreement to the PITT Agreement (the “Second PITT Amendment”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1711754/000121390023031332/0001213900-23-031332-index.htm
- Material Agreements
  Inmune Bio, Inc. amended INKmune Amendment with Immune Ventures, LLC (effective 2023-04-17).
  - Action: amendment
  - Agreement: license
  - Counterparty: Immune Ventures, LLC
  - Effective: 2023-04-17
  source text: On April 17, 2023, the Company entered into an additional amendment to the INKmune License Agreement (the “INKmune Amendment”) to remove the due diligence requirements of the INKmune License Agreement, including using reasonable commercial efforts to bring licensed products and services to market, removing all initiation of clinical trial requirements, and the filing of an NDA or equivalent upon successful completion of Phase III clinical trials.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1711754/000121390023031332/0001213900-23-031332-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.